Key Takeaway: Enveric Biosciences has entered into a licensing agreement with MycoMedica Life Sciences, potentially worth up to $62 million. This deal grants MycoMedica exclusive global rights to EB-002, a synthetic prodrug of psilocin, aimed at treating neuropsychiatric disorders such as depression. MycoMedica will handle the future development and commercialization of the drug.
Price reaction · baseline $85.932 (2024-11-11 close) · hit pre-market · 2 other ENVB headline(s) in the window, move may be shared
day 0 close
-7.4%
day 1
-14.6%
day 3 · peak
-23.5%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric secures a significant $62 million licensing deal.
MycoMedica gains exclusive global rights to a promising drug candidate.
Focus on non-hallucinogenic treatments aligns with current market trends.
Full Press Release Details
Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62 million, as the biotech company keeps its eye on its non-hallucinogenic treatments.
The agreement grants MycoMedica exclusive global rights to EB-002, a synthetic prodrug of psilocin, for treating neuropsychiatric disorders like depression, according to the company Tuesday. MycoMedica will be responsible for future development and commercialization of the compound.
Full Article >>
Frequently Asked Questions
What is the value of the licensing deal?
The licensing deal is worth up to $62 million.
What rights does MycoMedica gain?
MycoMedica gains exclusive global rights to EB-002.
What is EB-002 used for?
EB-002 is a synthetic prodrug of psilocin for treating neuropsychiatric disorders.
Who is responsible for the drug's development?
MycoMedica will handle the future development and commercialization of EB-002.